Torna alla classifica

Centene Corp (CNC)

Sottovalutato
HealthcareHealthcare PlansUnited States

Fondamentale

44

Prezzo

$62.12

Capitalizzazione

$30.89B

Parte 1 · Quanto vale l'azienda

Panoramica

Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment offers the temporary assistance for needy families; medicaid expansion; aged, blind, or disabled; and children's health insurance programs, as well as long-term services and supports; foster care; and medicare-medicaid plans. This segment also provides healthcare products and services. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual and commercial group. The Other segment operates clinical healthcare and pharmacies, as well as offers vision and dental, behavioral health, and centralized services. It provides services through primary and specialty care physicians, hospitals, behavioral health practitioners, and ancillary providers. The company was founded in 1984 and is headquartered in Saint Louis, Missouri.

Per questa società non c'è ancora una scheda redazionale

Concorrenti diretti

Con chi questa società si contende gli stessi clienti

Confronta

Generato il 18 settembre 2026 con claude-haiku-4-5 — condiviso con tutti gli utenti

P/E: 15.7Punteggio: 79Capitalizzazione: $85.57B

Elevance è il secondo operatore Medicaid dopo Centene e vende anche polizze sui mercati ACA con i marchi Anthem: le due si contendono gli stessi appalti statali e gli stessi iscritti individuali.

P/E: 23.6Punteggio: 80Capitalizzazione: $336.61B

La divisione Community & State di UnitedHealth è tra i cinque grandi del Medicaid ed è l'assicuratore più diffuso sui mercati ACA: si sovrappone alle linee Medicaid e Ambetter di Centene in quasi tutti gli Stati.

P/E: 22.6Punteggio: 64Capitalizzazione: $112.36B

Con Aetna, CVS Health è tra i cinque maggiori gestori Medicaid ed è un rivale diretto nel Medicare Advantage e nei piani per i doppiamente idonei, cioè gli stessi assistiti a carico pubblico di Centene.

P/E: 40.7Punteggio: 67Capitalizzazione: $46.78B

Humana si contende con il marchio Wellcare di Centene gli iscritti Medicare Advantage e Part D e concorre agli stessi appalti Medicaid statali, pur essendo molto più sbilanciata sugli anziani.

Molina Healthcare, Inc.MOH

Molina è l'azienda più simile a Centene: entrambe vivono di appalti Medicaid statali e di polizze ACA per famiglie a basso reddito, e si presentano alle stesse gare bandite dai singoli Stati.

Oscar Health, Inc.OSCR

Oscar vende quasi solo polizze sui mercati ACA in venti Stati ed è il principale sfidante di Ambetter, il marchio di Centene per le assicurazioni individuali.

Stato Patrimoniale e Liquidità

Ricavi

$178.66B

Ultimi 12 mesi (al 30/06/2026)

Utile Netto

$-5.10B

Ultimi 12 mesi (al 30/06/2026)

Free Cash Flow

$4.32B

Patrimonio Netto Totale

$19.95B

Passività Totali

$56.69B

Rapporto di Liquidità

1.15

Copertura Interessi

8.61

Debito/EBITDA

-

Utile per Azione

Ricavi e Utile Netto

Free Cash Flow

Scomposizione Ricavi

Prospetto storico

Margini nel tempo

Il debito nel tempo

Quanto pesa il debito

Griglia della crescita

Crescita — Ricavi

Stima del Fair Value

Caso generaleSottovalutato

Fair Value

$152.99

Prezzo Attuale

$62.12

Margine di Sicurezza

+59.4%

Range Fair Value

$99.44 - $206.54

Intervallo di dispersione tra i metodi di valutazione usati, non una stima statisticamente calibrata.

Metodi di Stima

Target degli analisti:$71.78
Flussi di cassa scontati (DCF):$254.50
Multiplo sugli utili (P/E):Dati insufficienti per calcolarlo
Formula di Graham:Dati insufficienti per calcolarlo
Valore della capacità di reddito (EPV):Dati insufficienti per calcolarlo
P/B giustificato:Dati insufficienti per calcolarlo
Sconto dei dividendi (Gordon):Dati insufficienti per calcolarlo
P/FFO, i fondi da operazioni:Dati insufficienti per calcolarlo
Utili di mezzo ciclo:$185.56
Multiplo sui ricavi:$1574.88
Consenso Analisti:Buy (12B / 14H / 1S)
Ultima Sorpresa Utili:+129.04%

Metriche di Valutazione

Rapporto P/E

-

ROE

-33.4%

Rapporto P/B

1.36

P/FCF

3.43

Margine Lordo

9.1%

ROIC

-10.5%

Radar Redditività

Creazione di Valore (Vantaggio Competitivo)

ROIC

-10.5%

WACC

8.0%

ROIC − WACC

-18.6 pp

Il ROIC è sotto il costo del capitale: l'azienda distrugge valore per ogni dollaro investito.

Criteri di Analisi Fondamentale

Superati (11)

  • Price CAGR 8.92%
  • P/FCF 3.43
  • P/B Ratio 1.36
  • Debt/Equity ratio
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Interest Coverage
  • Revenue Growth 5Y 24.5%
  • Earnings Surprise avg 161.0%
  • Share Dilution -5.8%

Non superati (11)

  • EPS shows upward trend
  • ROIC -10.5%
  • Gross Margin 9.1%
  • Operating Margin -3.2%
  • Return on Tangible Assets
  • Low reliance on intangibles
  • DCF valuation (Fairly valued)
  • ROE -24.0%
  • Analyst Consensus 44% Buy
  • Net Margin Trend -2.9% vs 1.3%
  • Piotroski F-Score 4/9

Non disponibili (5)

  • Dividend Payout NaN%
  • Debt/EBITDA
  • Price below Graham Number
  • PEG Ratio (need PE > 0 and growth > 0)
  • Earnings Quality (OCF/Net Income)

Piotroski F-Score

4/9

Segnali misti: alcune aree necessitano attenzione

score
criteria

Qualità degli Utili

-

Bassa qualità: indagare la contabilità

Diluizione Azionaria

-5.8%

Riacquisto azioni. Favorevole agli azionisti

Partecipazioni istituzionali

Governance

Team Dirigenziale

NomeRuoloEtà
Ms. Sarah M. LondonCEO & Director44
Mr. Andrew Lynn AsherExecutive VP & CFO56
Ms. Susan R. SmithChief Operating Officer49
Mr. Christopher Andrew KosterExecutive VP, General Counsel & Secretary60
Ms. Tanya M. McNallySenior VP & Chief People Officer51
Mr. Theodore Joseph PienkosCorporate Controller & Chief Accounting Officer43
Mr. Bradley BolivarChief Information Officer-
Ms. Jennifer Lynch GilliganSenior Vice President of Investor Relations-
Ms. Ashlee KnuckeyChief Risk, Ethics & Compliance Officer-
Ms. Cary D. HobbsExecutive VP & Chief of Staff57

Rischio Audit

2

Rischio CdA

2

Rischio Compensi

5

Rischio Diritti Azionisti

1

Parte 2 · Il prezzo e il momento d'ingresso

Questa parte non serve a capire se l'azienda vale: serve a scegliere quando comprarla, dopo che i fondamentali ti hanno convinto. Dentro: analisi tecnica, potenziale, drawdown storici, esposizione gamma.

Documenti

  • Relazione annuale (10-K)

    Una panoramica annuale del business, dei risultati finanziari e dei rischi dell'azienda.

    Depositato il 2026-02-17

    Vedi documento
  • Relazione trimestrale (10-Q)

    Un aggiornamento sull'andamento finanziario degli ultimi tre mesi.

    Depositato il 2026-07-28

    Vedi documento
  • Comunicazione price-sensitive (8-K)

    Una comunicazione su un evento importante, come un cambio ai vertici o un grande annuncio.

    Depositato il 2026-09-16

    Vedi documento

via SEC EDGAR

Storico Ricavi

via SEC EDGAR

Ultime Notizie

Ultime notizie per CNC, da Markets Gazette.

  • 7/28/2026POSITIVE
    Centene Boosts Guidance, Reports Favorable Medical Costs

    Centene Corporation has raised its annual profit guidance, signaling strong performance in the second quarter. The health insurer's improved outlook comes amid expectations that it can successfully navigate evolving government policies impacting the sector. This upward revision suggests robust operational execution and potentially better-than-anticipated medical cost management, which are key drivers for profitability in the health insurance industry. Investors will likely view this as a positive indicator of the company's resilience and future earnings potential.

  • 6/18/2026NEUTRAL
    If You Invested $100 In Centene Stock 20 Years Ago, You Would Have This Much Today

    An investment of $100 in Centene Corporation (CNC) stock twenty years ago would have yielded a significant return, though the exact figure is not provided in this summary. The article likely details the historical performance of Centene, a major managed care organization, over the past two decades. Investors considering Centene should analyze its long-term growth trajectory, market position within the healthcare sector, and any significant strategic shifts or regulatory challenges it has faced during this period to understand the drivers of its past performance and future potential.

  • 6/16/2026NEGATIVE
    Membership Slump Forces Health Giant Centene Into Staff Buyouts: Report

    Centene Corporation is implementing a significant cost-cutting initiative, offering voluntary buyouts to employees due to a notable decline in health plan enrollment. This move signals financial pressure and a strategic pivot to reduce operational expenses. Investors should monitor the effectiveness of these cost-saving measures and the company's ability to stabilize or grow its membership base in the coming quarters. The success of this plan will be crucial for future profitability and stock performance.

  • 3/25/2026NEUTRAL
    The youngest-ever female Fortune 500 CEO is reinventing the largest Medicaid insurer amid funding cuts and rising costs

    The article highlights the leadership of the youngest-ever female CEO at a Fortune 500 company, who is navigating Centene Corporation, a major Medicaid insurer, through a challenging environment of funding cuts and rising healthcare costs. While the article focuses on the CEO's strategic initiatives and the company's resilience, it does not provide specific financial performance data or forward-looking guidance that would directly impact stock valuation. Investors will be watching for how these strategies translate into tangible financial results in upcoming quarters.

  • 3/15/2026NEGATIVE
    Centene, Paramount Skydance, And Ulta Beauty Are Among Top 10 Large Cap Losers Last Week (March 9-March 13): Are the Others in Your Portfolio?

    Centene Corporation was among the top 10 large-cap decliners last week, with its stock price falling significantly. The broader market saw healthcare, media, beauty, and tech stocks leading the downturn. This decline was attributed to a combination of factors including earnings misses, weak forward-looking guidance provided by companies, downward analyst revisions, and challenging financing conditions. Investors are advised to monitor these headwinds closely as they impact sentiment and stock performance across various sectors.

  • 3/10/2026NEGATIVE
    Obamacare enrollment is plunging as costs soar, pushing down stocks like Centene

    Centene Corporation's stock is facing pressure as enrollment in the Affordable Care Act (ACA), also known as Obamacare, plummets. Soaring costs associated with the ACA are making health insurance plans less attractive, leading to a decline in policyholders. This trend directly impacts health insurers like Centene, which derive a significant portion of their revenue from ACA-compliant plans. The decrease in enrollment suggests lower premium revenues and potentially higher per-member costs for insurers, signaling a challenging financial outlook for the company and potentially others in the managed care sector.

via Markets Gazette